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Cross-sectional and longitudinal predictors of serum albumin (ESRD) patients treated by hemodialysis (HD) [1–11].
in hemodialysis patients. Albumin is the most abundant circulating plasma protein
Background. Lower serum albumin concentrations predict in the body and has a half-life in serum of approximatelyincreased mortality in hemodialysis (HD) patients. Many de-
20 days. It is synthesized by the liver and predominantlymographic, comorbidity, and modifiable treatment-related fac-
tors that predict HD patient outcomes may be associated with catabolized by vascular endothelium. Serum albumin
serum albumin. concentrations in maintenance HD patients may vary
Methods. Cross-sectional predictors of baseline albumin on because of changes in the albumin synthesis rate, re-December 31, 1993 were sought (N 5 3981). Additional effects
moval rate, or its volume of distribution. Because synthe-of the same baseline predictors on subsequent trends in albu-
sis is down-regulated by decreased nutrient intake, lowermin over one year were examined in a nested subsample of
patients (N 5 2245). Wave-1 of the United States Renal Data serum albumin is widely proffered as a visceral-protein
System Dialysis Morbidity and Mortality special study pro- marker for protein-energy malnutrition. Because synthe-
vided the data.
sis is also down-regulated in inflammatory states, lowerResults. Significant associations (P , 0.05) are summarized
serum albumin is also considered to be a negative acuteas older age, female gender, peripheral vascular disease, chronic
obstructive pulmonary disease, and cancer predicted a lower phase protein and therefore as a marker of inflammation.
baseline albumin and negatively influenced subsequent albu- Up to 50% of HD-treated patients may suffer from some
min trends. Baseline albumin was higher for blacks (vs. whites), degree of protein-energy malnutrition and suboptimallower for smoking and diabetes, and lower during the first year
nutrient intake [12]. Over one third of HD-treated pa-of HD treatment (,3 months and 3 to 12 months, vs. .1 year).
Trend analysis showed more positive albumin slopes for pa- tients display evidence of an inflammatory state, as indi-
tients in their first year on HD and more negative slopes for cated by elevated levels of positive acute-phase proteins
Native Americans (vs. whites). Baseline albumin was corre- [12–14]. Increases in dietary protein intake, which pro-lated with the type of vascular access being used [arteriovenous
mote higher albumin concentrations, are associated with(AV) fistulas . AV grafts . permanent catheters . temporary
a lower serum bicarbonate because of increased genera-catheters]. Trend analysis predicted more negative albumin
slopes for AV grafts and permanent catheters (vs. AV fistula tion of fixed acids. However, acidosis, which is a common
access). Baseline albumin correlated inversely with bicarbonate finding in severe chronic renal failure and before each
and directly with hematocrit. Dialysis with unmodified cellulose
dialysis treatment in maintenance HD patients, may it-membranes, without reuse, predicted lower baseline albumin
self promote hypoalbuminemia by increasing protein ca-than the other membrane-reuse categories.
Conclusions. Several exposures, which may be modifiable, tabolism and by reducing albumin synthesis [15–17].
were associated with serum albumin. Although albumin serves important biological func-
tions, it is generally suggested (but not proven) that lower
serum albumin is less causally related to poorer outcomes,
Predialysis serum albumin is an important predictor but is instead a marker for other harmful processes (in-
of morbidity and mortality in end-stage renal disease
flammation, suboptimal nutrient intake, acidosis). Corre-
lations such as those between inflammation, malnutri-
tion, and atherosclerotic disease [12, 18, 19] or betweenKey words: vascular access, bicarbonate, hematocrit, dialyzer machine.
nutrient intake and congestive heart failure [12] provide
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ing to an immunocompromised state could effect an in- ety of comorbid health conditions occurring within 10
years prior to SSD. For all patients, serum albumin wascreased risk for infectious complications [20–22].
Therefore, implementing strategies that increase se- requested for the month of study start and the preceding
six months (July through December 1993). For the nutri-rum albumin concentrations may confer survival benefits
in HD patients. However, as a prerequisite to successful tion-component subsample of patients, six subsequent
serum albumin measurements were requested to coverinterventions, a far better understanding is needed of
which aspects of current ESRD practices predispose a months 1, 3, 5, 7, 9, and 11 of the following calendar
year. The average delivered Kt/V over the six monthspatient to lower albumin concentrations. To this end,
this study investigated whether potentially modifiable preceding SSD was used as a predictor for the baseline
analysis, while average delivered Kt/V over the twoHD treatment exposures might correlate with lower se-
rum albumin, while simultaneously controlling for and months preceding SSD was used as a predictor for the
longitudinal analysis. Where delivered Kt/V was unavail-identifying the effects of demographic and comorbidity
covariates. Exposures examined included use of percuta- able, prescribed Kt/V was used, and the analyses were
adjusted to account for this change. The normalized pro-neous catheters and arteriovenous (AV) grafts (vs. fistu-
las), lower dialysis dose, use of less biocompatible dia- tein equivalent of total nitrogen appearance (nPNA) was
estimated by first calculating the protein catabolism ratelyzer membranes (cellulosic vs. other, 6 reuse) or use
of high-flux membranes (high flux vs. other, 6 reuse), (PCR) from midweek spKt/V [24] and then by normaliz-
ing for total body water. Total body water was as calcu-acidosis, and anemia. A national random sample of pa-
tients from the Dialysis Morbidity and Mortality Wave-1, lated from bioelectrical impedance-derived formulae
[25]. Patients missing data for laboratory predictor vari-USRDS Special Study, provided the data. First, pre-
dictors of serum albumin at a point prevalence date of ables at baseline (during December 1993) were excluded
from analysis.December 31, 1993, were established, and second, given
baseline serum albumin, the additional effects of the
Cross-sectional analysesbaseline characteristics on subsequent changes in serum
albumin concentrations were studied over a one-year The outcome variable for the cross-sectional analysis
was defined as the average of two serum albumin mea-period of follow-up.
surements in the two months prior to SSD, and 3981
patients were studied. Initial exploratory analysis consid-
METHODS
ered all bivariate relationships and possible nonlinearity
Data source in relationship with continuous predictors. A very small
number of patients were known to have AIDS (N 5 27)Data for this analysis were collected as part of
the USRDS Dialysis Morbidity and Mortality (DMMS) and had very low serum albumin levels. The analyses
did not seek inference for this small group of patients,Wave-1 study of a random sample of Medicare patients
who were alive on HD at the study start date (SSD) of who were therefore excluded without decreasing the
generalizable nature of the results for the majority ofDecember 31, 1993. A nutrition component, in a smaller
random subsample of patients, allowed examination of maintenance HD patients. The duration of ESRD at
study start was modeled as a categorical variable becausechanges in serum albumin concentrations, measured every
2 months over a 12-month period through November 30, we found a nonlinear relationship with serum albumin.
In all analyses, continuous variables were centered to1994. Data abstraction of medical records was done by
the patients’ dialysis facility staff through the 18 ESRD their mean values. Multiple linear regression was first
used to construct a base model that included age, gender,Networks under a contract with the Health Care Financ-
ing Administration (HCFA) of the U.S. Department of race, duration of ESRD, and those comorbidity factors
that were significantly associated with albumin in step-Health and Human Services.
The data abstraction forms for DMMS Wave-1 study wise regression at an a of 0.1. These were diabetes, periph-
eral vascular occlusive disease (PVOD), cancer andand DMMS Wave-1–Nutrition study were developed by
the USRDS-Coordinating Center and are published in chronic obstructive pulmonary disease (COPD), smok-
ing history, cerebrovascular disease, and congestive heartthe USRDS 1999 Annual Data Report, Appendix B [23].
Details requested for each patient included age, gender, failure. Then the association of each of the modifiable
practice-related factors with serum albumin was exploredrace, height, duration of ESRD prior to SSD, dialyzer
type, predialysis and postdialysis blood urea nitrogens adjusting for the variables in the base model. Finally,
the independent effect of each predictor variable was(BUNs), and weights for each of the six months preced-
ing SSD (to estimate delivered Kt/V according to the determined adjusting for all other predictors. Sensitivity
analyses explored the relationship between serum albu-Daugirdas forumulae), vascular access at SSD, labora-
tory variables at SSD (serum bicarbonate, serum choles- min and serum bicarbonate with and without adjustment
for nPNA. The residuals for all models were essentiallyterol, hematocrit), and the presence or absence of a vari-
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Table 1. Patient characteristics at study startnormally distributed, and obvious heteroscedasticity was
absent from residual plots. Cross-sectional Longitudinala
analysis analysis
Characteristic (N 5 3891) (N 5 2245)Longitudinal analyses
DemographicsA preliminary objective was to describe changes in
Age 59616 59616
serum albumin prior to death. For this purpose, unad- Gender % female 50 50
Race % white 50 50justed serum albumin trends during the six months be-
Race % black 40 39fore death or before study start were plotted for patients
Race % Asian 2 3
dying and for patients surviving during follow-up. Race % Native American 1 1
Duration of ESRDIn the main longitudinal analyses, the outcome of in-
,3 months 17 16terest was between-patient variation in serum albumin
3–12 months 19 19
trends. The serum albumin was measured repeatedly .1 year 64 65
Comorbid conditions % yesevery two months per patient for one year after study
Diabetes 32 31start. The goal was to determine whether in addition to
Peripheral vascular diseaseb 29 29
the cross-sectional correlations between predictors and Pulmonary disease (COPD) 12 13
Cancer 10 9baseline serum albumin, any further correlations existed
Coronary artery diseasec 43 43between these same predictors and trends in follow-up
Congestive heart failure 44 44
serum albumin. A sample of 2245 patients provided the Vascular access % yes
A-V graft 61.3 60.3data. All continuous variables were centered to their
A-V fistula 25.3 27.0mean values. Proc Mixed (SAS 6.12) was used to perform
Permanent catheter 5.5 5.4
multivariate repeated-measures analyses. Within-subject Temporary catheter 7.9 7.2
Dialysis membrane/reuse groupscorrelations between repeated serum albumin measure-
Reuse % yes 73 72ments were specified using a Toeplitz covariance matrix.
Unmodified cellulose, no reuse 14 16
In this design, observations separated by the same dis- Unmodified cellulose, reuse 27 26
Other low flux, no reuse 12 12tance in time, within a patient, are assumed to exhibit
Other low flux, reuse 17 18constant correlation. Proc Mixed uses all available albu-
High fluxd 29 28
min measurements without requiring complete albumin Baseline laboratory data
Serum albumin g/dL 3.7360.47 3.7360.44follow-up for each patient. Because the cross-sectional
Serum bicarbonate mEq/L 20.064.0 20.064.1baseline correlations had already been determined, all
KTV 1.1660.26 1.1760.28
of the longitudinal analyses sought additional effects on nPNA 1.0860.32 1.0960.32
Hematocrit % 3064 3064subsequent albumin trends adjusting for the baseline
serum albumin at study start. All models also included Data are presented as mean 6 SD or percent.
a Random subsample of patients from cross-sectional analysisadjustment for a regression to the mean effect. The ef-
b Includes history of claudication, amputation, absent foot pulses, and prior
fects of predictors on trends in follow-up serum albumin diagnosis of peripheral vascular disease
c Includes history of angina, myocardial infarction, coronary angioplasty, coro-concentrations are reported in terms of a delta serum
nary artery bypass surgery, or abnormal coronary angiography
albumin at one year: that is, for females versus males d Kuf . 20 mL/min/mm Hg; almost entirely reused (97% reused)
(starting with the same baseline serum albumin), the re-
ported delta serum albumin represents the projected aver-
age difference in serum albumin concentrations (g/dL)
in which serum albumin at six months (also at 12 months)between these two groups one year later. The actual
follow-up was classified as either clinically more desir-trends in the observed mean albumin concentrations dur-
able (that is, albumin $3.7 g/dL) or less desirable (thating follow-up for patients with baseline serum albumin
is, albumin ,3.7 g/dL). Adjusted odds ratios were sought#3.7 g/dL and .3.7 g/dL concurred with the predicted
for the associations of each of the covariates (examinedalbumin trends fit by the model, for an “average” patient
in the mixed model) with having a less desirable serumstarting at different levels of baseline albumin.
albumin. All analyses used the SAS Statistical SoftwareAs before, a base model was used that adjusted for
System version 6.12.the effects of age, gender, race, duration of ESRD at
study start, diabetes, PVOD, cancer, and COPD. The
associations of each of the modifiable practice-related RESULTS
factors with serum albumin trends were first explored
Univariate analysesseparately (adjusting for base model covariates) and then
Characteristics of both patient cohorts for the baselineanalyzed to determine the independent effects adjusted
and for the longitudinal analysis are shown in Table 1.for all other covariates. A sensitivity analyses used the
Both populations represent reasonably the HD patientmixed linear model to analyze serum albumin trends in
survivors only. A sensitivity analysis was also performed demographics in the United States for 1993 and 1994 [23].
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Table 2 and are expressed as the modeled additional
delta serum albumin at one year (g/dL). For example,
adjusting for serum albumin concentration at study start,
female gender was associated with a negative influence
on predicted serum albumin slope and therefore a nega-
tive delta serum albumin at one year (20.04, P 5 0.0065).
All else equal, the combined influence of these two sig-
nificant negative associations translate into an albumin
that was on average 0.10 g/dL lower at baseline and an
additional 0.04 g/dL lower at the end of one year for
females compared with males.
Fig. 1. Serum albumin during the six months before death for nonsurvi- For each 10-year older age, serum albumin was both
vors (r; 350 patients who died during one year of follow-up) compared 0.02 g/dL lower at baseline (P 5 0.0001) and an addi-with serum albumin during the six months prior to study start in 1476
tional 0.02 g/dL lower one year later (P 5 0.0007). Blacksprevalent ESRD patients (j; duration of ESRD .6 months at baseline)
who remained alive through to the end of the one-year follow-up. versus whites had a higher baseline serum albumin by
0.05 g/dL (P 5 0.0004) and had no significant difference
in subsequent trends. Native Americans versus whites
had no significant difference in baseline serum albumin
The marked similarity between the cohorts exists be- (P 5 0.59) but an average albumin that was 0.09 g/dL
cause the longitudinal analysis used a random subsample lower at the end of one year (P 5 0.027). For diabetic
of patients nested within the baseline study population. patients versus nondiabetic patients, baseline serum al-
Serum albumin at study start appeared normally dis- bumin was 0.09 g/dL lower (P 5 0.0001), but no subse-
tributed and had a mean value (6 SD) of 3.73 6 0.47 g/dL quent difference was seen in the trend analysis (P 5
in the baseline cohort and 3.73 6 0.44 in the longitudinal 0.51). Active smokers also had a 0.05 g/dL lower baseline
study cohort. Serum albumin was less than 3.7 g/dL in serum albumin (P 5 0.01).
39% of all patients at study start. Serum albumin showed Figure 2 plots the predicted baseline and additional
a significant correlation (P , 0.001) with other nutri- follow-up differences in serum albumin for those factors
tional surrogates, including predialysis creatinine (r 5 (excepting duration of ESRD), which were significantly
0.36), predialysis BUN (r 5 0.16), serum phosphorus (r 5 associated with serum albumin in both analyses. These
0.12), and serum cholesterol (r 5 0.08). Serum albumin factors included age, gender, PVOD, COPD, cancer (ex-
was negatively correlated with serum ferritin (r 5 20.09, cluding skin cancers), and a potentially modifiable expo-
P , 0.001) in a subset for whom ferritin data were col- sure, namely vascular access.
lected (N 5 1751). Baseline serum albumin was significantly higher for
Serum albumin declined prior to death in patients dying patients using AV fistulas than for any other type of
during the one year of follow-up. Figure 1 demonstrates vascular access. When compared with patients using AV
unadjusted time trends in serum albumin during the six fistulas, baseline serum albumin was 0.05, 0.11, and 0.15
months before study start for study survivors and during g/dL lower in patients dependent on AV grafts, perma-
the six months before death for study nonsurvivors. nent tunneled catheters, and temporary catheters, re-
spectively. Significant trend effects predicted further de-
Multivariate analyses
creases in serum albumin at one year for AV grafts and
The associations with serum albumin, evident from the permanent catheters versus fistulas (P 5 0.025 and P 5
cross-sectional analysis and the longitudinal (repeated 0.036, respectively). The overall effect predicted serum
measures) analysis, are presented in Table 2. Both mod- albumin concentrations to be 0.2 and 0.1 g/dL lower,
els adjust for confounding by all other predictor covari- respectively, for patients with permanent catheters and
ates. The cross-sectional correlations with baseline se- AV grafts versus AV fistulas (Fig. 2).
rum albumin are on the left in Table 2. The regression The associations of the other potentially modifiable
coefficients give both the magnitude and direction of exposures with the serum albumin concentration were
adjusted relationships between predictor factors and se- clinically and statistically significant at study start, but
rum albumin at study start and are labeled for interpreta- were not significantly modified during further follow-up.
tion as the delta baseline serum albumin (g/dL). For Baseline albumin was 0.04 g/dL lower (P 5 0.018) for
instance, baseline serum albumin was 0.10 g/dL lower those patients in the lowest quintile of baseline Kt/V
for females compared with males, all else equal in the (Table 2). Serum albumin was 0.06 g/dL higher in those
model (20.10, P 5 0.0001). Correlations with future reusing dialyzers (P 5 0.0001); this effect appeared pre-
trends in serum albumin over one year, adjusting for the dominantly because of significantly higher albumin in
patients reusing unmodified cellulosic membranes (0.10concentration at study start, are shown to the right in
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Table 2. Multivariate analyses of cross-sectional predictors of serum albumin at study start and additional longitudinal predictors of serum
albumin one year later
Cross-sectional Analysis Longitudinal analysisa
D Serum Additional D
albumin at serum albumin
baseline at 1 year
Factor g/dL SE P value g/dL SE P value
Age per 10 years older 20.02 0.005 0.0001 20.02 0.006 0.0007
Gender f vs. m 20.10 0.014 0.0001 20.04 0.016 0.0065
Black vs. white 0.05 0.015 0.0004 0.02 0.017 0.244
Native American vs. white 20.03 0.065 0.5933 20.09 0.039 0.027
Duration of ESRD
,3 months on HD vs. .1 year 20.20 0.024 0.0001 0.16 0.030 0.0001
3–12 months on HD vs. .1 year 20.05 0.018 0.004 0.06 0.019 0.0008
Diabetes vs. no 20.09 0.015 0.0001 20.01 0.018 0.5075
Peripheral vascular disease vs. no 20.07 0.016 0.0001 20.05 0.019 0.0037
Smoker vs. no 20.05 0.018 0.0114 20.004 0.022 0.8481
Chronic obstructive pulmonary disease vs. no 20.05 0.022 0.0136 20.05 0.024 0.0375
Neoplasm other than skin, vs. no 20.07 0.023 0.0034 20.10 0.027 0.0004
Cerebrovascular disease vs. no 20.03 0.020 0.1553 20.03 0.022 0.2417
Congestive heart failure vs. no 20.01 0.015 0.4472 20.02 0.016 0.2254
A-V graft vs. A-V fistula 20.05 0.017 0.0011 20.04 0.018 0.0253
Permanent catheter vs. A-V fistula 20.11 0.033 0.0009 20.09 0.041 0.0357
Temporary catheter vs. A-V fistula 20.15 0.031 0.0001 20.01 0.041 0.8672
spKt/V , 1.0 vs. $1.0 20.04 0.017 0.0183 20.01 0.019 0.6395
Unmodified cellulose, reuseb 0.10 0.022 0.0001 20.001 0.025 0.9641
Low flux synthetic/semisyntheticb 0.06 0.022 0.0062 20.03 0.025 0.2564
High flux synthetic/semisyntheticb 0.04 0.022 0.0487 0.02 0.024 0.3622
Hematocrit per 3% increment 0.05 0.005 0.0001 20.01 0.006 0.1994
Serum bicarbonate per 3 mEq/dL higher 20.03 0.005 0.0001 0.01 0.006 0.1914
a Longitudinal analysis also adjusts for: albumin concentration at study start, overall time trend, and regression to mean
b Versus unmodified cellulose no reuse
Fig. 2. Factors significantly associated with
serum albumin in both the cross-sectional and
longitudinal analysis, adjusting for all other co-
variates. Abbreviations are: PVOD, peripheral
vascular occlusive disease; COPD, chronic ob-
structive pulmonary disease; Perm C, perma-
nent percutaneous catheter. Symbols are: (j)
effect at study start; (h) follow-up effect.
g/dL) compared with patients dialyzing with the same trast, baseline serum albumin was inversely correlated
with baseline serum bicarbonate concentration, as shownmembrane but not reusing (P 5 0.0001). Dialysis with
low-flux and high-flux synthetic/semisynthetic membranes in Figure 3. An inverse trend remained following adjust-
ment for nPNA (Fig. 3), but was no longer statisticallycompared with unmodified cellulose (no reuse) was also
associated with significant positive effects on baseline significant.
The duration of ESRD at SSD was nonlinearly relatedserum albumin, respectively.
Baseline serum albumin was linearly related to base- to baseline serum albumin. Serum albumin at SSD was
on average 0.20 g/dL lower for patients in the first 3line hematocrit (P 5 0.0001). Higher hematocrits pre-
dicted higher serum albumin levels (0.05 g/dL higher months of ESRD and 0.05 g/dL lower for patients within
3 to 12 months of initiating ESRD treatment when com-serum albumin per 3 units higher hematocrit). In con-
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Fig. 4. Predicted albumin trends from the repeated-measures mixed
linear model for all patients using a single model and five different
levels of albumin (3.3, 3.5, 3.7, 3.9, and 4.1 g/dL) at study start areFig. 3. A linear inverse relationship existed between the predialysis
shown (dotted lines). Also, actual trends in the observed mean albuminserum albumin and the serum bicarbonate concentrations at baseline.
concentrations are shown for two study patient groups, those withFollowing the addition of nPNA as a covariate to the multivariate
baseline albumin (**) #3.7 and (*) .3.7 g/dL (solid lines).analysis, the linear relationship between serum albumin and serum
bicarbonate was no longer significant. Albumin was highest in the low
bicarbonate groups without (j; P 5 0.0005) or with (h; P 5 0.1239)
an adjustment for nPNA (aP 5 0.005; bP 5 0.076 vs. reference group).
at six months into the study did not suggest additional
associations to those reported for the mixed model.
pared with subjects greater than one year on dialysis
DISCUSSION(P , 0.005; Table 2). However, during one year of follow-
up, serum albumin increased 0.16 and 0.06 g/dL in pa- A number of cross-sectional studies have focused on
tients less than 3 months or 3 to 12 months on ESRD serum albumin as a predictor variable [26–28]. This study
focuses on serum albumin as an outcome variable. Ittreatment, respectively, compared with the trend in sub-
assesses potentially modifiable exposures as predictorsjects greater than one year on dialysis at study start (P ,
of serum albumin not just by cross-sectional analysis,0.001; Table 2). In a sensitivity analysis of 1895 patients
but also using longitudinal analysis. All analyses simulta-who survived to the end of the study, serum albumin
neously define at-risk patient groups with demographicalso increased by 0.16 and 0.06 g/dL in those less than
and comorbidity adjustments. The validity of the study3 months or 3 to 12 months on ESRD treatment, respec-
is strengthened by the multivariate nature of the analy-tively, compared with subjects greater than one year on
ses, the use of all available albumin follow-up data in thedialysis at study start (P , 0.003).
repeated-measures analysis, and the random selection ofThe veracity of the longitudinal analysis for modeling
a nationally representative sample of dialysis patients.repeated measures of albumin over time is demonstrated
A priori hypotheses existed for all of the associationsin Figure 4. Figure 4 shows the observed mean serum
considered in this study.albumin measurements for patients with baseline albu-
Among the prior observational studies that examinedmin ,3.7 and $3.7 g/dL, and the modeled trends in
serum albumin trends, the serum albumin concentrationserum albumin (given five different specified levels of
was recorded monthly over 18 months in a highly se-starting albumin) predicted by the longitudinal analysis
lected group of undernourished HD patients receiving
base model. There is good agreement between the ob-
intradialytic parenteral nutrition [29], recorded every six
served trends and the model predicted trends. In an months over two years in a large sample of incident
analysis limited only to study survivors with baseline HD patients [7], and recorded monthly over the first six
albumin concentration ,3.7 g/dL, the observed mean months of treatment in 115 new HD patients [30]. The
serum albumin concentration increased by 0.25 g/dL dur- latter study provides insight into the dynamic relation-
ing the study. This indicates that the increase in serum ship between serum albumin and proteinuria over the
albumin concentration in patients with lower starting first six months of ESRD treatment [30]; the study by
albumin is not simply an effect of attrition of sicker Culp et al focuses on serum albumin as a time-dependent
individuals. Model-predicted trends for the 1895 study risk factor for mortality [7], while the study by Chertow
survivors also paralleled closely those given in Figure 4 et al addresses the effects of intradialytic parenteral nu-
for the entire study population. An additional multivari- trition on albumin and mortality [29]. The longitudinal
ate sensitivity analyses using logistic regression to predict multivariate-adjusted component of the present analyses
adds substantially to these existing data by examiningthe odds of an undesirable serum albumin (,3.7 g/dL)
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multiple predictors of serum albumin trends over time, ance, and these characteristics may influence survival in
dialysis patients [33]. Therefore, as with dose, mortalityincluding potentially modifiable treatment practices.
Clinically, the most significant relationship was argua- analyses will be needed to define optimal dialyzer and
reuse practices.bly seen with vascular access. Patients dialyzing through
native AV fistulas appeared to have both higher serum Metabolic acidosis (low serum bicarbonate) is a com-
mon finding in HD-treated patients. Chronic metabolicalbumin levels at study start and more positive trends in
serum albumin over time when compared with patients acidosis has been shown to increase protein catabolism
and amino acid oxidation, and to decrease albumin syn-using either AV grafts or permanent percutaneous cathe-
ters. The finding at baseline may suggest better preceding thesis in experimental models, in healthy volunteers, and
in patients with chronic renal failure [15, 16, 34–36].care, including nutrition, among patients with AV fistu-
las, while the positive trends may relate to lower rates These effects should combine to decrease the serum al-
bumin concentration. By modifying dialyzate bicarbon-of infection and access interventions with AV fistulas.
The observation supports NKF-DOQI recommenda- ate concentration and/or using oral supplementation,
metabolic acidosis could be easily prevented in mainte-tions to increase the utilization of native AV fistulas [31].
Dialysis dose had a marginal, albeit significant, inde- nance dialysis patients without any change in dietary
protein intake. Might such acidosis correction then bependent effect on serum albumin at baseline only in those
patients substantially underdialyzed by current recom- beneficial in terms of serum albumin concentrations?
At least two randomized controlled clinical trials inmended targets. A number of additional analyses of the
effects of delivered Kt/V, modeled as a continuous covar- HD-treated patients have found no increase in serum
albumin concentrations following correction of meta-iate and in quintiles with a variety of cut points, provided
no additional evidence for a significant relationship be- bolic acidosis [37, 38]. However, both these studies were
limited by the selection of “stable” HD patients, in whomtween Kt/V and serum albumin in either cross-sectional
or longitudinal analyses. It is recognized that a priori the mean baseline serum albumin concentration ap-
proached 4 g/dL. In contrast, a small, one-group studya stronger relationship might have been expected with
dialysis dose. However, others have similarly found that of 12 patients with a mean baseline serum albumin of
3.5 g/dL found the serum albumin increased significantlyan increased dialysis dose within recommended targets
had a minimal effect on nutritional markers (abstract; coincident with correction of acidosis [39]. Cross-sec-
tional observational analyses have consistently describedKloppenburg et al, J Am Soc Nephrol 8:198A, 1997) [26].
This analysis in no way proposes to suggest that lower an inverse correlation between serum bicarbonate con-
centrations and the serum albumin (abstract; Dumler etdoses are acceptable, and the authors believe that investi-
gations on dose-mortality relationships should guide HD al, J Am Soc Nephrol 8:191A, 1997) [26, 27]. The HEMO
study group reported that lower serum bicarbonate cor-dose delivery.
Overall, the practice of dialyzer reuse was correlated related cross sectionally, albeit not significantly, with
higher baseline serum albumin, but also significantly withwith a slightly higher albumin at baseline. Low biocom-
patibility associated with the first use of unmodified cel- higher baseline measurements of all of the following
nutritional markers: nPNA, reported dietary protein in-lulosic membranes appeared to explain most of this ef-
fect. Dialysis with these membranes (without reuse) was take, predialysis BUN, predialysis serum creatinine, and
serum phosphorus [27]. Higher dietary protein intakeassociated with significantly lower albumin concentrations
compared with all other membrane groups. In a con- promotes acidosis in HD patients by increasing the rate
of fixed acid generation, but it also independently sup-trolled clinical trial, Parker et al have previously pro-
vided convincing data of a positive relationship between ports albumin synthesis. Thus, it is proposed that a pro-
portionately greater independent positive influence ofimproved biocompatibility and weight gain and serum
albumin over time in HD patients [32]. Serum albumin increased dietary protein intake on albumin synthesis
confounds a description of the negative influence of aci-appeared marginally higher at baseline in the unmodified
cellulose/reuse group versus the low-flux synthetic/semi- dosis-related catabolism on the serum albumin concen-
tration.synthetic membrane group (0.04 g/dL, P , 0.04) and
versus the high-flux membrane groups (0.06 g/dL, P , We also found serum bicarbonate levels to be inversely
correlated with nPNA. After adjusting for nPNA, the0.01). The longitudinal analyses showed a small and non-
significant improved trend in albumin in the high-flux inverse linear association between bicarbonate and albu-
min was no longer significant. Additional adjustmentmembrane group. Concerns over greater intradialytic
protein losses with some high-flux membranes may relate for predialysis serum concentrations of creatinine, urea
nitrogen, phosphorus (6 ferritin) did not further alterin part to the larger baseline difference in the high-flux
membrane group; however, this study design could not the relationship or provide any evidence for increased
albumin with increased bicarbonate. These adjustmentsaddress this issue. Benefits of high-flux dialyzers include
improved biocompatibility and middle molecule clear- were an attempt to indirectly control for confounding
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by dietary protein intake (6 inflammation). In the longi- treatment and serum albumin to avoid bias is emphasized
for both cross-sectional and prospective studies of nutri-tudinal analysis, no evidence could be found for an asso-
ciation between baseline serum bicarbonate and serum tional markers in ESRD patients.
Evidence was found for some regression of serum al-albumin trends over one year (adjusted for serum albu-
min at study start). Plausibly, in acidotic patients, oppos- bumin concentrations to the mean. However, it is empha-
sized that the average observed and predicted albumining independent effects of increased catabolism and in-
creased nutrient intake on serum albumin trends could in those patients starting with an albumin ,3.7 g/dL,
while modestly improved, nonetheless remained lessefface each other to yield this result. Again, the longitudi-
nal analysis suffers from the same limitations of incom- than 3.7 g/dL at one year. In the majority of hypoalbumi-
nemic patients, current treatment approaches as imple-plete adjustment for confounding effects of protein in-
take and inflammation. To date, neither observational mented do not appear, therefore, to optimize serum al-
bumin over time. Moreover, while the trend in the meanstudies nor clinical trials have satisfactorily addressed the
hypothesis that avoidance of chronic metabolic acidosis serum albumin over time was flat in those patients with
starting albumin levels $3.7 g/dL, nonetheless, 15% ofmight augment the serum albumin concentration in some
HD-treated patients. albumin measurements available for survivors in this
group were ,3.7 g/dL at the end of one year.A significant positive linear correlation between he-
matocrit level and serum albumin concentration has been Cross-sectional studies have reported important asso-
ciations of serum albumin with C-reactive protein (CRP),previously noted and is confirmed by this study. Lower
hematocrit and albumin levels may be codependent on a positive acute-phase protein [12–14], and with nPNA
[13, 26, 27]. Data on CRP were not collected in thisinflammatory mechanisms that contribute to erythropoi-
etin resistance and decreased albumin synthesis, respec- study. On average, nPNA behaves as a proxy for dietary
protein intake and is positively correlated with the serumtively [28]. Anemia may also be in part consequent on
poor nutrition [28]. In these scenarios, correcting the albumin concentration (as was the case in this study),
suggesting that increased catabolism plays only a minor,anemia directly with more erythropoietin and/or blood
transfusion would not be expected to improve the albu- if any, role in raising the nPNA. Adjustments for nPNA
and/or CRP could enhance the predictive power of thesemin concentration. However, anemia can have profound
effects on well-being in dialysis patients, and to the extent analyses, but would represent adjustment for mecha-
nisms through which an exposure might lead to a lowerthis contributes to decreased nutrient intake, anemia
correction might augment nutritional well-being. or higher serum albumin. Such adjustment could obscure
associations between exposures and the serum albumin.Intuitively predictable associations were identified be-
tween the presence of diabetes, PVOD, cancer, chronic For similar reasons, the other laboratory indicators of
nutrition or inflammation (creatinine, predialysis BUN,pulmonary disease and increasing age, and lower albu-
min concentrations. The observed gender effect and the serum phosphorus, cholesterol, ferritin) are also not ad-
justed for in the main analyses.race group effects were more surprising. The analysis
suggests that careful attention be paid to serum albumin A possible bias in assessing predictors of longitudinal
trends in serum albumin might occur if early follow-in older patients, women, Native Americans, and pa-
tients in the previously mentioned comorbidity groups. up deaths were more prominent in one category of a
predictor variable. For example, if a disproportionateThe negative correlation between female gender (fe-
males have improved survival on dialysis vs. males) and number of unhealthy diabetics (vs. unhealthy nondiabet-
ics) with lower or decreasing serum albumin die earlylower serum albumin concentration (a predictor of de-
creased survival on dialysis) highlights the importance of then proportionally more healthy diabetic patients (vs.
healthy nondiabetics) with higher serum albumin con-adjusting survival analyses for gender and serum albumin
levels when describing the independent predictive effects centrations will survive. In this instance, the longitudinal
model might conclude that serum albumin appears toof either of these covariates.
The duration of ESRD treatment at the study start increase more over time in diabetics. No bias of this
nature was uncovered in a sensitivity analysis examiningsignificantly influenced serum albumin baseline levels
and trends over time. A lower albumin concentration is predictors of trends in serum albumin in survivors only
(that is, excluding those who because of death duringexpected in new dialysis patients because of a combina-
tion of poor nutrition, dilutional effects, and residual the period follow-up could not contribute data on late
follow-up serum albumin measurements).proteinuria [7, 9, 32]. The survivor-only sensitivity analy-
sis in this study and the analyses of previous studies [9] Many of the exposures examined, such as demograph-
ics and comorbidity variables, may not be modifiable.suggest the rise in albumin in incident HD patients is
not due simply to the death of sicker patients during the They are included to strengthen the adjustment for con-
founding and are identified as potential confounding co-first 6 to 12 months of treatment. The need to adjust for
the nonlinear associations between duration of ESRD variates that need to be adjusted to allow interpretation
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